FIELD: medicine.
SUBSTANCE: group of inventions refers to ophthalmology. The group of inventions discloses the pharmaceutical use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof effective as an agent for preventing or treating an ocular disease accompanied by an optic nerve disorder which represents glaucoma, glaucomatous optic nerve neuropathy or glaucomatous visual field constriction. The preparation is a dosage form of eye drops, ophthalmic ointments, an insert, a dressing, an injection, a tablet, a delayed release granule or a capsule. The mode of introduction represents introduction into a vitreous body, a conjunctival sac, instillations, subconjunctival, sub-Tenon's or oral introduction.
EFFECT: group of inventions provides a suppressive effect on the retinal ganglion cell protection.
12 cl, 3 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
GLAUCOMA TREATMENT | 2018 |
|
RU2759998C2 |
AGENTS ADJUSTING, INHIBITING OR MODULATING ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTORS (CTGF) AS UNIQUE DRUGS FOR INTRAOCULAR TENSION REDUCTION AND TREATMENT OF GLAUCOMA RETINOPATHIES/OPTICAL NEUROPATHIES | 2003 |
|
RU2332213C2 |
METHOD FOR TREATMENT OF GLAUCOMOUS OPTIC NEUROPATHY BY MEANS OF TRANSPLANTATION OF 3D CELLULAR CULTURE OF MULTIPOTENT MESENCHIMAL SCLERAL SULCUS STEM CELLS | 2016 |
|
RU2623646C1 |
METHOD FOR EARLY DIAGNOSIS OF LOW-TENSION GLAUCOMA | 2023 |
|
RU2816038C1 |
METHOD OF COMBINED TREATMENT OF GLAUCOMATOUS OPTIC NEUROPATHY | 2010 |
|
RU2472475C2 |
APPLICATION OF SERUMAL AMYLOID GENE A IN DIAGNOSTICS AND TREATMENT OF GLAUCOMA AND DETERMINATION OF ANTIGLAUCOMA AGENTS | 2004 |
|
RU2365379C2 |
ANTAGONISTS CDK2 AS ANTAGONISTS OF SHORT FORM OF C-MAF TRANSCRIPTION FACTOR FOR GLAUCOMA TREATMENT | 2004 |
|
RU2370267C2 |
APPLICATION OF SERUM AMYLOID A GENE FOR DIAGNOSIS AND THERAPY OF GLAUCOMA AND IDENTIFICATION OF ANTIGLAUCOMATOUS AGENT | 2007 |
|
RU2461378C2 |
METHOD FOR PREDICTION OF PRIMARY OPEN-ANGLE GLAUCOMA | 2012 |
|
RU2483306C1 |
AGENT FOR USE IN TREATMENT OR PREVENTION OF OPHTHALMOLOGICAL DISORDERS | 2020 |
|
RU2812055C1 |
Authors
Dates
2013-08-27—Published
2009-02-27—Filed